We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.68B
AUM Growth
+$199M
Cap. Flow
-$1.42B
Cap. Flow %
-30.22%
Top 10 Hldgs %
50.13%
Holding
119
New
17
Increased
19
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$29M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$27.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$27M
4
AMED
Amedisys
AMED
+$25.5M
5
RVMD icon
Revolution Medicines
RVMD
+$22.6M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$52.3M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$48.8M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$39.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$36.6M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 68.03%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNRHW
101
DELISTED
Senior Connect Acquisition Corp. I Warrant
SNRHW
– –
-500,000
Closed -$19.6K
EUCRW
102
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
– –
-333,333
Closed -$13.5K
EUCRU
103
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
– –
-1
Closed -$10
1 2 3 4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2023 Portfolio in Review

As of Q2 2023, Deerfield Management held 119 positions worth $4.68B, up 4.4% from $4.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deerfield Management withdrew a net $1.42B in Q2 2023, closing 18 positions and reducing 10 holdings. Its most notable exit was Mirum Pharmaceuticals, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intercept Pharmaceuticals, Inc. worth $23M.

  • Deerfield Management's largest Q2 2023 buy was Intercept Pharmaceuticals, Inc.: 2,077,893 shares worth $23M.
  • Deerfield Management added most to Amedisys in Q2 2023, an estimated $25.5M increase.
  • Deerfield Management's biggest Q2 2023 reduction was Neurocrine Biosciences, cutting an estimated $52.3M.
  • Deerfield Management fully exited Mirum Pharmaceuticals in Q2 2023, selling an estimated $48.8M.
  • Deerfield Management's ten largest holdings make up 50% of its $4.68B portfolio in Q2 2023.
  • Deerfield Management opened 17 new positions and closed 18 in Q2 2023.
  • Deerfield Management's portfolio value rose 4.4% quarter-over-quarter to $4.68B.

Based on Deerfield Management's 13F filing for Q2 2023, filed 14 Aug 2023.